Close mobile menu×
Close mobile menu

David J. Cohen, MD

Board Certifications: 
Nephrology, Internal Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-6469

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Nephrology
  • Internal Medicine

Clinical Expertise

  • Transplantation Nephrology
  • Kidney Transplant
  • Hypertension

Education & Training

  • Albert Einstein College of Medicine - Yeshiva University
  • Internship: Mount Sinai Hospital
  • Residency: Mount Sinai Hospital
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Brigham & Women's Hospital

About David Cohen

I am involved in numerous clinical protocols investigating new immunosuppressive drugs and/or new combinations of existing medications in renal transplant patients, both newly transplanted patients and those with long-term functioning transplants.

Academic Titles

  • Professor of Medicine at CUMC

Administrative Positions

  • Medical Director, Renal Transplantation

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Languages

  • French

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Indemnity
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Indemnity
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
622 West 168th Street
New York, New York 10032
Phone:
(212) 305-6469
Fax:
(212) 305-9642
Primary

Research

I am interested in immunosuppressive drug protocols in renal transplantation, as well as renal disease occurring in recipients of non-renal transplants.

Grants

OBSERVATIONAL STUDY PROTOCOL IM103076 EVALUATING NULOJIX LONG TERM SAFETY IN TRANSPLANT ENLIST REGISTRY (P&S Industry Clinical Trial)

Aug 14 2013 - Aug 14 2018

A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS (P&S Industry Clinical Trial)

Feb 8 2013 - Feb 8 2018

DRUG LEVEL VARIABILITY IN CHILDREN AFTER RENAL TRANSPLANT AND TRANSITION OF CARE (Federal Gov)

Jul 1 2015 - Jun 30 2016

C10-004 (P&S Industry Clinical Trial)

Jun 23 2011 - Jun 23 2016

NATURAL HISTORY OF INFECTION CAUSED BY BK VIRUS (AND OTHER OPPORTUNISTIC VIRAL PATHOGENS ) IN RENAL AND RENAL-PANCREAS TRANSPLANT RECIPIENTS (Federal Gov)

Oct 1 2013 - Sep 27 2015

A 12 MONTH, MULTI-CENTER, RANDOMIZED, OPEN-LABEL NONINFERIORITY STUDY COMPARING THE SAFETY AND EFFICACY OF CONCENTRATION (P&S Industry Clinical Trial)

Sep 14 2010 - Sep 14 2015

A PHASE 3, OPEN-LABEL,MULTICENTER,PROSPECTIVE, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF CONVERTING STABLE KIDNEY T (P&S Industry Clinical Trial)

Mar 18 2009 - Sep 30 2014

PLANNED TRANSITION TO SIROLIMUS-BASED THERAPY VERSUS CONTINUED TACROLIMUS-BASED THERAPY IN RENAL ALLOGRAFT RECIPIENTS (P&S Industry Clinical Trial)

Jul 22 2009 - Jul 22 2014

AN OPEN LABEL, MULTICENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPI (P&S Industry Clinical Trial)

Jun 25 2009 - Jun 25 2014

LCP TOCRO 2017 (P&S Industry Clinical Trial)

Nov 12 2008 - May 31 2014

Selected Publications

  • Wilkinson AH, Cohen DJ. (1999) Renal failure in recipients of non-renal solid organ transplants. J Amer Soc Nephrol 10:1136-45
  • The Mycophenolate Mofetil Acute Rejection Study Group. (2001) Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. Transplantation 71:1091-7
  • Lin J, Valeri AM, Cohen DJ, Radhakrishnan J. (2002) Angiotensin converting enzyme (ACE) inhibition in chronic allograft nephropathy. Transplantation 73:783-8
  • Adams PL, Cohen DJ, Danovitch GM, et al. (2002) The nondirected live-kidney donor: ethical considerations and practice guidelines. Transplantation 74:582-90